- Current manufacturing of pharmaceutical proteins is low volume, high cost and slow. Producing 100 million doses within weeks requires radical changes. - Genencor has experience producing industrial proteins at large scale and low cost. Their approach uses high-yielding microbial fermentation and efficient downstream processing. - They demonstrate production of a monoclonal antibody within Aspergillus fungi at 1 g/L yield. A two-step purification process isolates the antibody, which has similar properties and pharmacokinetics as one produced in CHO cells. - Their tools and methods can produce over 100 million doses of a protein drug within 12 weeks of identifying the target, allowing rapid responses to pandemics or bioterrorism threats.